Key result
Recent evidence raises serious doubts about the superiority of ticagrelor over clopidogrel in reducing mortality in acute coronary syndrome due to data discrepancies and industry bias in the PLATO trial.
Why the study?
Does ticagrelor reduce mortality in patients with acute coronary syndrome compared to clopidogrel?
Does ticagrelor reduce mortality in patients with acute coronary syndrome compared to clopidogrel?
Answers are grounded in this paper and cite their sources.
This editorial highlights recent investigations questioning the validity of the PLATO trial results, suggesting that ticagrelor may not be superior to clopidogrel for reducing mortality in ACS due to industry-related data discrepancies.
Señor Editor:En el ensayo clínico multicéntrico, randomizado, doble ciego, PLATO, publicado en 2009 1 , en que se comparó el antiplaquetario clopidogrel con ticagrelor, este último, de acuerdo a los autores, resultó superior al clopidogre l , en particular en reducción de la mortalidad, a los 12 meses, en 18,624 pacientes admitidos a un hospital, con un síndrome coronario agudo (SCA), con o sin elevación del segmento ST.Basado en dicho estudio, la FDA aprobó su uso en 2011, en el SCA, a pesar de la oposición y objeciones de varios revisores.Posteriormente algunos estudios randomizados fallaron en replicar los resultados del PLA-TO.Actualmente, las guías sobre el uso de antiplaquetarios en el SCA recomiendan el ticagrelor por sobre el clopidogrel.
No takes yet. Share an insight, caveat, or question.
Alexis Lama Toro (2025) conducted a letter in Acute coronary syndrome (ACS) (n=18,624). Ticagrelor vs. Clopidogrel was evaluated on Mortality. Recent evidence raises serious doubts about the superiority of ticagrelor over clopidogrel in reducing mortality in acute coronary syndrome due to data discrepancies and industry bias in the PLATO trial.
Synapse has enriched 10 related papers. Consider them for comparative context: